Discovery of new targets for the treatment of Parkinson’s disease
The HOPE 4 PD project aims to validate two G protein coupled receptors (GPCRs), whose expression is altered in the striatum of patients with Parkinson’s disease, as targets of drugs to treat neuro-degenerative diseases, Parkinson’s disease being the first indication. The project also includes various approaches to identify original compounds able to modulate the activity of these receptors. This would allow the initiation of an innovative drug discovery programme for Parkinson’s disease, including the development of original chemical molecules, and the demonstration of efficacy in animal models.
Consortium
Companies: Euroscreen (Coordinator), UCB
Universities:: ULB, UNamur
Research center: Certech
